RESUMO
Cryoglobulinemia is defined by the presence of immunoglobulins having the following characteristics: forming a gel when temperature is <37 °C, precipitate in a reversible manner in the serum, and redissolve after rewarming. The presence of both polyclonal IgG and monoclonal IgM (type II), or of polyclonal IgG and polyclonal IgM (type III) identifies the mixed cryoglobulinemia (MC). The identification of the Hepatitis C virus (HCV) infection in most of the cases previously defined as "essential" represented a cornerstone in the understanding the pathogenesis of this condition. The picture of MC comprehends heterogeneous clinical presentations: from arthralgias, mild palpable purpura, fatigue to severe vasculitis features with skin necrotic pattern, peripheral neuropathy and, less commonly, lungs, central nervous system, gastrointestinal tract, and heart involvement. The kidney represents the most common organ presentation, and the presence of glomerulonephritis is a key element when considering prognosis. We discuss the clinical presentation and histological features, diagnostic pitfalls, and controversies in the management of patients with cryoglobulinemic glomerulonephritis, with a special focus on reporting our experience in treating patients with B cell depletion therapy.
Assuntos
Crioglobulinemia , Glomerulonefrite , Hepatite C Crônica , Antivirais/efeitos adversos , Antivirais/uso terapêutico , Artralgia/etiologia , Linfócitos B , Biópsia , Estudos de Coortes , Crioglobulinemia/complicações , Crioglobulinemia/diagnóstico , Crioglobulinemia/patologia , Crioglobulinemia/terapia , Crioglobulinas/isolamento & purificação , Erros de Diagnóstico , Fadiga/etiologia , Glomerulonefrite/diagnóstico , Glomerulonefrite/etiologia , Glomerulonefrite/patologia , Glomerulonefrite/terapia , Glomerulonefrite Membranoproliferativa/patologia , Glomerulosclerose Segmentar e Focal/patologia , Hepatite C Crônica/complicações , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Fatores Imunológicos/uso terapêutico , Imunossupressores/uso terapêutico , Rim/patologia , Depleção Linfocítica/métodos , Masculino , Pessoa de Meia-Idade , Troca Plasmática , Prognóstico , Estudos Prospectivos , Púrpura/tratamento farmacológico , Púrpura/etiologia , Púrpura/patologia , Rituximab/uso terapêutico , Vasculite/etiologiaRESUMO
Low-protein diets (LPDs) are often considered as contraindicated in diabetic patients, and are seldom studied. The aim of this observational study was to provide new data on this issue. It involved 149 diabetic and 300 non-diabetic patients who followed a LPD, with a personalized approach aimed at moderate protein restriction (0.6 g/day). Survival analysis was performed according to Kaplan-Meier, and multivariate analysis with Cox model. Diabetic versus non-diabetic patients were of similar age (median 70 years) and creatinine levels at the start of the diet (2.78 mg/dL vs. 2.80 mg/dL). There was higher prevalence of nephrotic proteinuria in diabetic patients (27.52% vs. 13.67%, p = 0.002) as well as comorbidity (median Charlson index 8 vs. 6 p = 0.002). Patient survival was lower in diabetic patients, but differences levelled off considering only cases with Charlson index > 7, the only relevant covariate in Cox analysis. Dialysis-free survival was superimposable in the setting of good compliance (Mitch formula: 0.47 g/kg/day in both groups): about 50% of the cases remained dialysis-free 2 years after the first finding of e-GFR (estimated glomerular filtration rate) < 15 mL/min, and 1 year after reaching e-GFR < 10 mL/min. In patients with type 2 diabetes, higher proteinuria was associated with mortality and initiation of dialysis. In conclusion, moderately restricted LPDs allow similar results in diabetic and non non-diabetic patients with similar comorbidity.